Psychoactive therapeutics promote neurite outgrowth

Newsletter # 101



In vitro models


Neuroactive compounds hold promise for therapeutic efficacy in treating neuronal dysfunction due to their ability to stimulate neurite outgrowth, that in turn results in a structural and functional remodeling of neuronal circuits in the brain.


Neurofit’s historical data indicated that different pharmacological class of drugs - with clinically proven neuropsychiatric benefits - promote neurite outgrowth of neurons.


  • Exposure of neuronal cultures with the following Anxiolytics and/or antidepressants drugs enhances neurite outgrowth as measured by an increased total neurite length:


  • ■ Reboxetine is a norepinephrine reuptake inhibitor (NRI);
    ■ Venlafaxine and Imipramine are Serotonine Norepinephrine Reuptake Inhibitors (SNRI);
    ■ Amitriptyline is a monoamine reuptake inhibitor and
    ■ Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI)





    ***, p ≤ 0.001 significantly different as compared to Control group



  • Exposure of neuronal cultures with the following Cognitive enhancers enhances neurite outgrowth as measured by an increased total neurite length:

  • ■ Memantine is a NMDA receptor antagonist;
    ■ Donepezil is an Acetylcholineesterase (AChE) inhibitor;
    ■ Pre-084 and 4-IBP are sigma-1 receptor agonists (S1R) associated with various in-vivo CNS effect including cognitive benefit 1,2

    1: 10.1016/0006-8993(96)00565-3
    2: 10.1016/j.biocel.2020.105803


    *, p ≤ 0.05; ***, p ≤ 0.001 significantly different as compared to Control group


    Ask for more informations



NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us, we will reply within few days. Custom protocol

On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please :

sign up on our mailing list